BPC-157 may be particularly suited to this route of administration due to its known neuroprotective benefits
This is most relevant to some GHRH and GHRP related peptides, including compounds such as CJC-1295, CJC-1295 + DAC, Sermorelin, Tesamorelin, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin
While concerning for users, this shedding typically indicates the treatment is working and resolves within 2-8 weeks
Our other popular research products, like our BPC-157 and KPV peptides, also require careful reconstitution, and our guidelines are consistent across all of our products
Antioxidants role in regulating oxidative stress
BPC-157 BPC-157 was not prohibited prior to 2022, but the clinically unapproved experimental peptide was added to the 2022 WADA Prohibited List under the S0 Unapproved Substances category